| Oral candidiasis |
| Variable |
POR |
95% CI |
c2 |
p |
| Gender |
|
|
|
|
| Female |
1 |
- |
- |
- |
| Male |
0.3 |
0.05-1.76 |
1.92 |
0.19 |
| Use of antimicrobials |
|
|
|
|
| Yes |
1 |
- |
- |
- |
| No |
1.11 |
1.03-1.18 |
0.54 |
0.6 |
| Susceptibility |
|
|
|
|
| Intermediate |
1 |
- |
- |
- |
| Sensitive |
0.14 |
0.02-0.74 |
6.7 |
0.03 |
| CD4 lymphocytes |
|
|
|
|
| <50 |
1 |
- |
- |
- |
| 51-100 |
5.9 |
0.91-38.25 |
4.32 |
0.09 |
| Time since HIV diagnosis |
|
|
|
|
| <1 month |
1 |
- |
- |
- |
| >1 month |
5.92 |
0.91-38.25 |
4.32 |
0.09 |
| Age group (years) |
| 17-29 |
1 |
- |
- |
- |
| 30-39 |
1.12 |
0.19-6.60 |
0.89 |
0.63 |
| 40-49 |
1.43 |
0.18-11.2 |
0.72 |
0.56 |
| ≥50 |
1.64 |
0.12-20.9 |
0.7 |
0.57 |
| Esophageal candidiasis |
| Gender |
|
|
|
|
| Female |
1 |
- |
- |
- |
| Male |
1.18 |
0.22-6.1 |
0.04 |
0.6 |
| Use of antimicrobials |
|
|
|
|
| Yes |
1 |
- |
- |
- |
| No |
1.35 |
0.14-12.7 |
0.7 |
0.63 |
| Susceptibility |
|
|
|
|
| Intermediate |
1 |
- |
- |
- |
| Sensitive |
0.06 |
0.01-0.36 |
14.7 |
0.001 |
| CD4 lymphocytes |
|
|
|
|
| <50 |
1 |
- |
- |
- |
| 51-100 |
0.73 |
0.64-0.83 |
2.13 |
0.16 |
| Time since HIV diagnosis |
|
|
|
|
| <1 month |
1 |
- |
- |
- |
| >1 month |
1.54 |
0.26-9.02 |
0.23 |
0.46 |
| Age groups (years) |
|
|
|
|
| 17-29 |
1 |
- |
- |
- |
| 30-39 |
1.62 |
0.50-5.25 |
0.41 |
0.3 |
| 40-49 |
1.14 |
0.25-5.02 |
0.85 |
0.57 |
| ≥ 50 |
1.33 |
0.20-8.70 |
0.76 |
0.55 |
| POR, prevalence odds ratio. |
|
|
|
|
|
